Cohance Lifesciences to Invest $18 Million in NJ Bio and Aruka Bio
Cohance Lifesciences announced an $18 million investment to enhance its antibody-drug conjugate strategy, including $13 million to increase its stake in NJ Bio from 56% to 67.3%, and $5 million to acquire a 65% controlling interest in Princeton-based Aruka Bio. The reorganisation aims to integrate NJ Bio's services with Cohance's manufacturing capabilities, supporting end-to-end CRDMO development. Completion is expected by September 2026, subject to agreements and customary conditions.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (51/100). Lens Score 37/100.
Outlets measured: economictimes, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (50–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Sept, 05:02 pm. Other outlets followed.
- 1